Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials by Boussageon, Rémy et al.
Effect of intensive glucose lowering treatment on all
cause mortality, cardiovascular death, and
microvascular events in type 2 diabetes: meta-analysis
of randomised controlled trials
Rémy Boussageon general practitioner and lecturer
1, Theodora Bejan-Angoulvant cardiologist,
pharmacologist, and lecturer
2 3 4, Mitra Saadatian-Elahi epidemiologist
2, Sandrine Lafont resident
in family medicine
1, Claire Bergeonneau resident in family medicine
1 3, Behrouz Kassaï
pharmacologist and lecturer
2 3 4 5, Sylvie Erpeldinger general practitioner and lecturer
1, James M
Wright anaesthesiologist, pharmacologist, and professor of anaesthesiology and pharmacology
6,
François Gueyffier head of department and clinical investigation centre, cardiologist, and
professor
2 3 4 5, Catherine Cornu endocrinologist, pharmacologist, and research physician in clinical
investigation centre
2 3 4 5
1Department of General Medicine, Université Claude Bernard Lyon 1, Lyon, France;
2Department of Clinical Pharmacology, Hospices Civils de
Lyon, Lyon, France;
3UMR 5558, CNRS, Villeurbanne, France;
4Université Claude Bernard Lyon 1, Lyon, France;
5Clinical Investigation Centre,
Louis Pradel Hospital, Bron, France;
6Departments of Anaesthesiology, Pharmacology, and Therapeutics and Medicine, University of British Columbia,
Vancouver, BC, Canada
Abstract
Objective To determine all cause mortality and deaths from
cardiovascular events related to intensive glucose lowering treatment
in people with type 2 diabetes.
Design Meta-analysis of randomised controlled trials.
Data sources Medline, Embase, and the Cochrane database of
systematic reviews.
Study selection Randomised controlled trials that assessed the effect
of intensive glucose lowering treatment on cardiovascular events and
microvascular complications in adults (≥18 years) with type 2 diabetes.
Data extraction Primary end points were all cause mortality and death
from cardiovascular causes. Secondary end points were severe
hypoglycaemia and macrovascular and microvascular events.
Synthesis of results Results are reported as risk ratios with 99%
confidence intervals. Statistical heterogeneity between trials was
assessed with χ², τ², and I
2 statistics. A fixed effect model was used to
assess the effect on the outcomes of intensive glucose lowering versus
standard treatment. The quality of clinical trials was assessed by the
Jadad score.
Results 13 studies were included. Of 34 533 patients, 18 315 received
intensive glucose lowering treatment and 16 218 standard treatment.
Intensive treatment did not significantly affect all cause mortality (risk
ratio 1.04, 99% confidence interval 0.91 to 1.19) or cardiovascular death
(1.11, 0.86 to 1.43). Intensive therapy was, however, associated with
reductions in the risk of non-fatal myocardial infarction (0.85, 0.74 to
0.96, P<0.001), and microalbuminuria (0.90, 0.85 to 0.96, P<0.001) but
a more than twofold increase in the risk of severe hypoglycaemia (2.33,
21.62 to 3.36, P<0.001). Over a treatment period of five years, 117 to
150 patients would need to be treated to avoid one myocardial infarction
and 32 to 142 patients to avoid one episode of microalbuminuria,
whereas one severe episode of hypoglycaemia would occur for every
15 to 52 patients. In analysis restricted to high quality studies (Jadad
score >3), intensive treatment was not associated with any significant
risk of reductions but resulted in a 47% increase in risk of congestive
heart failure (P<0.001).
Conclusions The overall results of this meta-analysis show limited
benefits of intensive glucose lowering treatment on all cause mortality
and deaths from cardiovascular causes. We cannot exclude a 9%
reduction or a 19% increase in all cause mortality and a 14% reduction
or a 43% increase in cardiovascular death. The benefit:risk ratio of
Correspondence to: C Cornu, Centre d’Investigation Clinique, Hôpital Louis Pradel, 48, Avenue du Doyen Lépine, 69500-Bron, France
catherine.cornu@chu-lyon.fr
Extra material supplied by the author (see http://www.bmj.com/content/343/bmj.d4169/suppl/DC1)
Results of sensitivity analyses restricted to high quality studies
Reprints: http://journals.bmj.com/cgi/reprintform Subscribe: http://resources.bmj.com/bmj/subscribers/how-to-subscribe
BMJ 2011;343:d4169 doi: 10.1136/bmj.d4169 Page 1 of 12
Research
RESEARCHintensive glucose lowering treatment in the prevention of macrovascular
and microvascular events remains uncertain. The harm associated with
severe hypoglycaemia might counterbalance the potential benefit of
intensive glucose lowering treatment. More double blind randomised
controlled trials are needed to establish the best therapeutic approach
in people with type 2 diabetes.
Introduction
Worldwide, the number of adults with diabetes was estimated
at 150 million in 2000, a figure that is expected to increase to
366 million by 2030.
1 Epidemiological evidence indicates that
type 2 diabetes is an independent risk factor for cardiovascular
disease and microvascular complications, such as retinopathy.
The rate of cardiovascular disease is about twice as high in
peoplewithdiabetesthanwithout.
2 3Intensiveglycaemiccontrol
hasbeensuggestedasaneffectivetreatmenttoreducetheburden
of cardiovascular disease and microvascular complications in
people with diabetes.
4 Current guidelines recommend a target
glycated haemoglobin level (HbA1c) of 7% or less.
5 The results
of major randomised clinical trials on the benefits of such
treatmentare,however,controversial.
6-8IntheActiontoControl
CardiovascularRiskinDiabetes(ACCORD)studyanintensive
glucose lowering regimen was associated with increased
mortality (hazard ratio 1.22, 95% confidence interval 1.01 to
1.46, P=0.04).
7 In three major recent trials the rates of
hypoglycaemiaandweightgainweresignificantlyhigherinthe
groups receiving intensive therapy. In none of these studies did
intensivetherapydecreasecardiovascularevents.Astatistically
significant reduction in the rate of microvascular and renal
events after intensive glycaemic control was reported in the
United Kingdom Prospective Diabetes Study (UKPDS) 33 on
intensive blood glucose control with sulfonylureas or insulin
comparedwithconventionaltreatmentandriskofcomplications
in patients with type 2 diabetes
9 and the Action in Diabetes and
Vascular disease: preterAx and diamicroN mr Controlled
Evaluation(ADVANCE)
6trial,whereasintheVeteransAffairs
Diabetes Trial (VADT)
8 microvascular complications were the
same in both the intensive therapy and the control groups.
Severalmeta-analysesevaluatingtheeffectofintensiveglucose
lowering in people with diabetes are currently available.
However, these published meta-analyses
10-12 focused mainly on
the effect of treatment on macrovascular events, such as
myocardialinfarction.Wecarriedoutanupdatedmeta-analysis
takingintoconsiderationbothmicrovascularcomplicationsand
cardiovascular events as well as severe hypoglycaemia related
to intensive glycaemic control and the level of evidence of the
selected studies.
Methods
We searched for studies through Medline, Embase, and the
Cochrane database of systematic reviews (January 1950 to July
2010) without any language restriction. Key words used were
“type2diabetes”,“diabetesmellitus”,“cardiovasculardiseases”,
“coronary disease”, “stroke”, “peripheral vascular diseases”,
“retinopathy”, “neuropathy”, “albuminuria”, “renal failure”,
“congestive heart failure”, “hypoglycaemic agents”, “glucose
control”, “glycaemic control”, and “tight glucose control”.
Furthermore, we reviewed the reference lists of published
meta-analyses. Overall, 147 abstracts were reviewed.
Study selection
Two investigators (RB, SL) independently reviewed the
identified abstracts or manuscripts to determine the eligibility
of the studies for inclusion in the meta-analysis. Eligibility
criteriawererandomisedcontrolledtrialsassessingtheefficacy
of intensive glucose lowering treatment (oral or insulin) versus
a standard treatment (standard care), less intensive glycaemic
lowering treatment, or placebo (intensive glycaemic treatment
could be defined either by a specified HbA1c target or by
treatment intensification); trials using clinically relevant
outcomes;andparticipantsaged18orolderwithtype2diabetes.
Quality assessment
Two independent investigators (RB, CC) used the Jadad score
to assess the quality of selected articles.
13 Double blind
randomised placebo controlled trials received a score of more
than 3, whereas open randomised trials were given a score of 3
or less.
End points
Primary end points were all cause mortality and death from
cardiovascular causes. Secondary end points were myocardial
infarction, non-fatal myocardial infarction, stroke (fatal and
non-fatal), congestive heart failure, photocoagulation,
retinopathy (new or worsening), visual deterioration or
blindness, neuropathy (new or worsening), microalbuminuria
(new or worsening), renal failure (occurrence of renal failure
ordoublingofserumcreatininelevel),peripheralvascularevents
(legrevascularisation,peripheralarterialdisease,orintermittent
claudication), amputation, and severe hypoglycaemia.
Definitionsofbothprimaryandsecondaryendpointscorrespond
to those reported in the originally published papers. These
criteria were not available for all studies included in the
meta-analysis.Evaluationswerenotalwaysbasedontheoverall
study population.
Two reviewers (RB and CC) independently and in duplicate
extracted data for all the outcomes of interest from the included
trials.
Statistical analysis
To standardise the reporting of our results we calculated risk
ratios and 99% confidence intervals from the number of events
orparticipantsineachgroupforeverytrial.Weusedfixedeffect
model meta-analysis to assess the effect of intensive glucose
loweringversusstandardtreatmentontheoutcomesofinterest.
The χ² (P<0.1) and I² statistics were used to assess statistical
heterogeneity across trials. The I² statistic is derived from
Cochran’s Q—that is, [(Q−df/Q)×100]—and measures the
proportion of overall variation that is attributable to between
study heterogeneity. The statistical test of heterogeneity was
significant if the P value was less than 0.1, and heterogeneity
was considered high if the I² statistic was greater than 50%. To
determinethesizeandclinicalrelevanceofheterogeneitywhen
detected by means we calculated τ². We used a random effect
model when the statistical test of heterogeneity showed
significance.
To illustrate the impact of treatment strategy, we derived the
range of absolute risk reductions by computing the range of the
risks for the end point considered in the control group of the
three most powerful and recent trials (ACCORD, ADVANCE,
and VADT) over a five year period. We then multiplied the
extreme values of this range by the common risk reduction
estimate.Thenumberofpatientsneededtobetreatedtoprevent
(benefit) or provoke (harm) an event was the opposite of the
absolute risk reduction.
SensitivityanalysiswascarriedoutaccordingtotheJadadscore.
When possible we carried out all statistical analyses according
to the intention to treat principle. Because of multiple
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RESEARCHcomparisons, all P values were two sided (P<0.01). Analyses
were done using Revman software version 5 (www.cc-ims.net/
revman).
Results
Figure 1 shows the selection of studies. Eight trials were
excluded: the Diabetes Control and Complications Trial
(DCCT)
14 concerned people with type 1 diabetes; the Diabetes,
Insulin Glucose Infusion in Acute Myocardial Infarction
(DIGAMI) trial
15 evaluated the effect of short term glycaemic
control in people with acute myocardial infarction; A Diabetes
Outcome Progression Trial (ADOPT)
16 and Rosiglitazone
Evaluated for Cardiac Outcomes and Regulation of Glycemia
in Diabetes (RECORD)
17 did not assess intensive glucose
loweringtreatmentordrugversusplacebo;DiabetesREduction
Assessment with ramipril and rosiglitazone Medication
(DREAM)
18andNateglinideAndValsartaninImpairedGlucose
Tolerance Outcomes Research (NAVIGATOR)
19 concerned
patients with impaired glucose tolerance; STENO 2
20 tested
several interventions and therefore did not assess intensive
glucose lowering treatment compared with standard treatment;
and the UKPDS 44
21 reported intermediate end points rather
than clinical end points of interest for this meta-analysis.
Overall, 13 randomised controlled trials fulfilled the inclusion
criteria and were included in the meta-analysis.
6-9 22-30 The table
summarises the baseline characteristics of the selected studies.
Trials included five double blind controlled trials with a Jadad
scoreofmorethan3(UGDPphenformin,
22UGDPtolbutamide,
23
PROactive,
28 Dargie et al,
29 Hyperinsulinemia: the Outcome of
its Metabolic Effects (HOME)
30) and eight open trials with a
Jadadscoreof3orless(UGDPinsulin,
24theKumamotostudy,
25
Veterans Affairs Feasibility Study 1997,
26 31 UKPDS 33,
9
UKPDS34,
27ACCORD,
7 32 33ADVANCE,
6andVADT
8).These
studies’ results on microangiopathy were published separately:
VADT
31 and ACCORD.
32 33
The UGDP studies, one on phenformin versus placebo
22 the
otherontolbutamideversusplacebo
23werecombined.Asthese
drugs have been withdrawn, a sensitivity analysis was carried
out with the combined trial excluded from the meta-analysis.
A further UGDP study evaluated the effect of intensive versus
standard insulin therapy in people with diabetes.
24 The UKPDS
33
9 and 34
27 studies were combined. Contrary to an earlier
meta-analysis,
10 the control group (n=411) was included only
onceinthepresentstudy.UGDPandUKPDSincludedpatients
with either diabetes or impaired glucose tolerance. However,
the mean plasma glucose at inclusion—143.2 mg/100 mL in
UGDP and 8·0 mmol/L (range 7.1-9.7) and 8·1 mmol/L
(7.1-9.7), in UKPDS 33 and 34, respectively, are compatible
with the diagnosis of diabetes. A sensitivity analysis without
UGDP and UKPDS was done.
The analysis was based on 34 533 patients (60% men), with a
mean age of 62 (range 49-66) years, a baseline mean HbA1c
level of 7.9% (range 7.1-9.5%), and a mean body mass index
of 31 (range 20-32). The mean duration of diabetes was 7.8
(range 0-12) years. Overall, 39% of patients already had a
cardiovascular event at baseline. In total, 18 315 were
randomised to the intensive treatment group and 16 218 to the
standard treatment group. The mean duration of follow-up was
5.0 (range 1-10) years.
Primary end points
Intensivetreatmentdidnotsignificantlyaffectallcausemortality
(risk ratio 1.04, 99% confidence interval 0.91 to 1.19) or death
from cardiovascular causes (1.11, 0.86 to 1.43; fig 2).
Heterogeneity between trials was significant for all cause
mortality (P=0.09, τ
2=0.01, I
2=42%) and for cardiovascular
deaths (P=0.006, τ
2=0.04, I
2=61%). After exclusion of trials
with a Jadad score of 3 or less (see web extra), the estimated
odds ratio for all cause mortality did not change (1.06, 0.84 to
1.34), whereas the rate of cardiovascular deaths tended to be
higher, although not significantly, in the intensive treatment
group (1.58, 0.60 to 4.17). Heterogeneity among high quality
trials was persistent for the rate of cardiovascular deaths
(I
2=70%). This heterogeneity could not be explained.
Secondary end points
Figure 3 summarises the effect of intensive treatment versus
standard treatment on macrovascular complications. In the
intensive treatment group the rate of non-fatal myocardial
infarctions was significantly reduced (0.85, 0.74 to 0.96;
P<0.001) and there was a non-significant trend towards a
reduction of all myocardial infarctions (0.90, 0.81 to 1.01;
P=0.02). No heterogeneity existed between trials for these end
points (I
2=0%). However, no trial showed a significant risk
reduction by itself on these two criteria. When trials of high
quality (see web extra) were only considered, the observed
benefit for non-fatal myocardial infarctions (0.83, 0.63 to 1.10)
disappeared and the rate of all myocardial infarctions tended to
be higher, although not significantly, in the intensive treatment
group (1.34, 0.77 to 2.35). Data on all myocardial infarctions
werenotavailableforthePROactivestudy.
28Forallmyocardial
infarctions, the five year absolute risk reduction ranged from
0.7% to 0.9%. The number of patients needed to be treated to
prevent one event was 150 to 117.
Intensive treatment was not associated with a reduction in the
risk of non-fatal strokes (1.00, 0.83 to 1.21; fig 3), all strokes
(0.96, 0.83 to 1.13; fig 3), or congestive heart failure (1.17, 0.91
to 1.50; fig 4). Heterogeneity was evident among studies for
congestive heart failure (P=0.01, τ
2=0.04, I
2=59%), but not for
the two other end points. The analysis restricted to high quality
trials (see web extra) could be carried out only for all strokes
(0.81, 0.57 to 1.17) and for congestive heart failure (1.47, 1.19
to 1.83).
Figures 5-7 summarise the effect of intensive treatment versus
standard treatment on microvascular complications. Intensive
treatment was associated with a significant reduction in only
oneendpoint—therateofmicroalbuminuria(0.90,0.85to0.96;
fig6).Thisresultreliesmainlyonthreelargertrials:ACCORD,
7
ADVANCE,
6 and UKPDS.
27 Absolute risk reductions for
microalbuminuriarangedfrom0.7%to3.1%.Thecorresponding
numbers for patients needed to be treated were 142 to 32. The
rateofperipheralvasculareventsdidnotdifferbetweenthetwo
groups (0.98, 0.84 to 1.13; fig 6). Heterogeneity between trials
for this end point was not significant (P=0.16, I
2=34%). When
the analysis was limited to high quality studies (see web extra),
the risk of peripheral vascular events remained non-significant
(1.34, 0.95 to 1.90).
The intensive treatment and standard treatment groups did not
differ in the rate of retinopathy (0.85, 0.71 to 1.03; fig 5),
photocoagulation(0.91,0.71to1.17;fig5),visualdeterioration
or blindness (1.00, 0.96 to 1.05; fig 6), neuropathy (0.99, 0.95
to 1.03; fig 6), renal failure or doubling of serum creatinine
levels (1.03, 0.98 to 1.08; fig 6), and fatal or non-fatal
amputation (0.84, 0.54 to 1.29; fig 7). Between trial
heterogeneity was observed for retinopathy (P=0.03, τ
2=0.02,
I
2=54%) and for photocoagulation (P=0.07, τ²=0.02, I
2=57%).
After exclusion of trials with a Jadad score of less than 3 (see
webextra),heterogeneitydisappearedandtheeffectofintensive
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RESEARCHtreatmentwasnolongersignificantformicroalbuminuria(0.99,
0.87to1.13).TheexclusionoftheUGDPtrial(phenforminand
tolbutamide trials combined) did not change the results.
Severe hypoglycaemia
Compared with the standard treatment group, the risk of severe
hypoglycaemia was more than twice as high in the intensive
treatment group (2.33, 1.62 to 3.36; fig 8). Heterogeneity was
evidentamongstudies(P=0.03,τ
2=0.05,I
2=63%).Absolutefive
year risk increases in severe hypoglycaemia ranged from 1.9%
to6.6%,makingthenumberofpatientsneededtoharmbetween
52 and 15.
Discussion
Thismeta-analysisofdatafrom13randomisedcontrolledtrials
showed no benefit of intensive glucose lowering treatment on
allcausemortalityordeathfromcardiovascularcausesinadults
with type 2 diabetes. Furthermore, a 19% increase in all cause
mortality and a 43% increase in death from cardiovascular
causes cannot be ruled out. Other meta-analyses have shown a
significant 15% relative reduction in the rate of non-fatal
myocardial infarctions.
10-12 Only one study (ACCORD
7) found
a protective effect of intensive treatment on myocardial
infarction, counterbalanced by an increase in overall mortality.
A reduction in myocardial infarctions without a reduction in
mortality must be considered cautiously. Since it is estimated
that 50% of patients with myocardial infarctions die before
receiving medical attention, a reduction of myocardial
infarctionsshouldhavesomeimpactonthemortality.Intensive
glucose lowering treatment was associated with a significant
10% reduction in the risk of microalbuminuria, without
significant benefit on other important clinical microvascular
complications such as neuropathy, retinopathy, visual
deterioration,orrenalfailure.Thefavourableresultsonnon-fatal
myocardial infarction and microalbuminuria did not remain
significant when the analysis was restricted to studies of high
quality (Jadad score >3), whereas a 47% increase in the risk of
congestive heart failure became significant. As reported by
others, intensive treatment was associated with a significant
twofold increased risk of severe hypoglycaemia.
Strengths and limitations of the study
Our meta-analysis is more powerful (seven trials and 34 533
patients)thanpreviouslypublishedmeta-analysesintheAnnals
ofInternalMedicine(fivetrialsand27802patients)andLancet
(fivetrialsand33040patients).Previousmeta-analysesfocused
on cardiovascular events but not on microvascular events
(retinopathy,nephropathy)orperipheralarterialdisease.Finally,
we present the results using numbers needed to treat and
numbers needed to harm, which allows benefits and harms to
be balanced in a more explicit way.
Another strength of this meta-analysis was to carry out a
sensitivity analysis based on the level of evidence.
Randomisation and concealment of allocation are of central
importance in clinical trials to prevent selection bias, but they
do not prevent biases related to the evaluation, the follow-up,
or the “placebo effect.” This is why double blinding is required
to reduce bias when evaluating a specific treatment effect. We
exploredtheimpactofblindingbytestingwhetherthetreatment
effectwassensitivetotheremovaloftrialsthatwerenotblinded.
This analysis did not change our conclusions.
This study has some limitations. As in other meta-analyses,
publication bias may occur. The treatment strategies applied
and the targeted glycaemic level (if any) varied across trials, as
did the definitions of outcomes, trial designs, and duration of
follow-up.Thisislikelytoexplainatleastsomeoftheobserved
heterogeneity.
Policy implications
Overall, the absolute benefit of treatment for five years was
modest; 117 to 150 people would need to be treated to avoid
one myocardial infarction, 32 to 142 to avoid one episode of
microalbuminuria, and 15 to 52 to avoid one severe
hypoglycaemicevent.Theoccurrenceofseverehypoglycaemia
has been strongly related to the incidence of major
macrovascular events in a retrospective analysis of the
ADVANCE study
6 (hazard ratio 2.88, 95% confidence interval
2.01 to 4.12), major microvascular events (1.81, 1.19 to 2.74),
death from cardiovascular causes (2.68, 1.72 to 4.19), and all
cause mortality (2.69, 1.97 to 3.67).
34
Our analyses emphasise the lack of high quality trials to
investigate the impact of intensive glucose lowering treatment
on the occurrence of macrovascular and microvascular events
in people with type 2 diabetes. We also emphasise the overall
low level of evidence on the efficacy of glucose lowering
treatment compared with other kinds of preventive measures
against cardiovascular events.
The absence of benefits from intensive glucose lowering
treatmentfurtherillustrateswhyrelyingonsurrogateendpoints
fortreatingpeopleisafallacy.Marketingnewdrugsbasedonly
on evidence that they decrease glucose or HbA1c plasma levels,
or both, should not be allowed. Practitioners (and patients)
should not rely on either blood glucose targets or HbA1c targets
or the concept of “the lower the better.” A recent retrospective
cohortstudyreportedasignificantincreaseinallcausemortality
inpeopleinthelowest10thsforHbA1clevel(6.4%,hazardratio
1.52, 95% confidence interval 1.32 to 1.76) and highest 10ths
(10.5%, 1.79, 1.56 to 2.06).
35
Itisparadoxicaltoproposeintensiveglucoseloweringtreatment
when available drugs have no proved intrinsic efficacy. Most
clinical trials evaluating the efficacy of drugs to lower glucose
levelsinpeoplewithdiabetesusedHbA1clevelsastheprimary
outcome,
36 37 and this is considered sufficient for licensing. In
addition, few double blind placebo controlled trials have
evaluated treatments for diabetes based on clinically relevant
criteria.
22 23 28-30
Comparison of results with individual drug
trials
From available data, metformin is the most effective oral
treatment for glycaemic control in overweight people with
diabetes,
38 39despitenumerouslimitationsoftheUKPDSstudy
40
and lack of adequately proved efficacy. Metformin’s ability to
achieve weight loss rather than weight gain and lack of risk of
hypoglycaemia makes it the first line treatment in international
guidelines.
5 On the contrary, sulfonylureas have no proved
efficacy in randomised placebo controlled double blind trials.
38
Although the ADVANCE study
6 did not show an excess risk
of mortality with glicazide MR, doubts persist about its safety.
For example, UKPDS 34 calls into question the combination
of metformin and sulfonylureas (all cause mortality risk ratio
1.60,95%confidenceinterval1.02to2.52).
27Onemeta-analysis
of retrospective cohort studies reported a significant 24% to
61% excess risk for all cause mortality associated with first
generationsulfonylureas.Secondgenerationsulfonylureaswere
associated with an excess risk of 18% to 30% for congestive
heart failure.
41
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RESEARCHRosiglitazonewasrecentlywithdrawnfromtheEuropeanmarket
and restricted for use by the US Food and Drug Administration
for safety reasons.
42 The benefit:risk ratio of pioglitazone
remains unclear
43 given its associated risk of congestive heart
failureandweightgain.
28Weobservedsignificantheterogeneity
for the outcome of congestive heart failure, which was not
entirely explained by using thiazolidinediones in the intensive
treatment group (>90% of patients for ACCORD
7 and 100%
forPROactive
28versus<20%forADVANCE
6).Inouranalysis,
the increased risk of congestive heart failure remained after the
exclusion of trials using glitazone. The use of sulfonylureas
41
or insulin in patients with heart failure
44 might also explain the
observed risk.
The effectiveness of long acting insulin therapy in type 2
diabetes has not been confirmed yet. Given the risk of severe
hypoglycaemia
34andapossibleincreaseinmortality,
45especially
for patients with diabetes and heart failure,
44 the benefit:risk
ratio also seems to be uncertain in the prevention of
microvascular and macrovascular complications.
New therapeutic drug classes for glucose lowering treatment
shouldbeevaluatedbyrandomisedclinicaltrialsagainstplacebo
(on top of another treatment) using clinical outcomes. A more
global approach to decrease the risk of cardiovascular disease,
such as blood pressure lowering drugs and statins, should also
be systematically considered when treating people with type 2
diabetes.
Conclusion
The overall results of this meta-analysis do not show a benefit
of intensive glucose lowering treatment on all cause mortality
or cardiovascular death. A 19% increase in all cause mortality
and a 43% increase in cardiovascular mortality cannot be
excluded.Thesmallbenefitonnon-fatalmyocardialinfarctions
and microalbuminuria may be offset by a significant increase
in the risk of severe hypoglycaemia. The analysis, restricted to
high quality studies, showed no benefit but a significantly
increased risk of congestive heart failure in patients receiving
intensive glucose lowering treatment. In light of these findings,
more high quality randomised trials assessing morbidity and
mortalityoutcomesarewarrantedtoestablishthebestapproach
for glucose lowering in people with type 2 diabetes.
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RESEARCHTable
Table 1| Characteristics of studies included in meta-analysis
Total
HOME
2009
30
VADT
2009
8
ADVANCE
2008
6
ACCORD
2008
7
Dargie et al
2007
29
PROactive
2005
28
UKPDS 1998
9 27
Veteran
Affairs
26
Kumamoto
1995
25
UGDP
1982
24
UGDP
1975,
22
1976
23 Characteristic
4 3 3 3 5 5 3 2 2 3 4 Jadad score
34 533 390 1791 11 140 10 251 224 5238 4209 153 110 414 613 No of
participants
18 315 196 892 5571 5128 110 2605 3071 75 55 204 408 No receiving
intensive
therapy
16 218 194 899 5569 5123 114 2633 1138 78 55 210 205 No receiving
standard
therapy
60* 50 97 58 62 80 66 47 100 50 29 29 Men (%)
61.8* 61 60 66 62 64 62 53 60 49 52 52 Age (years)
31* 30 31 31 32 29 31 28 31 20 NA NA Body mass
index
7.8* 12 11.5 8 10 4 8 <1 7.8 6.5 <1 <1 Duration of
knowndiabetes
(years)
5* 4.3 5.6 5 3.5 1 2.9 10 2.3 6 10 10 Follow-up
(years)
39* 1 40 32 35 35 100 0 27 0 9.5 9.5 Patients with
previous
cardiovascular
events (%)
— — — — — — — 1.45 — — 1.43 1.43 Initial FPG (g/L)
7.9* 7.9 9.4 7.5 8.3 7.8 7.9 7.1 9.5 9 — — Initial HbA1c (%)
6.7* 7.7 6.9 6.8 6.4 7.3 7.0% 7.0 7.0 NA NA NA Final HbA1c (%)
intensive group
7.5* 7.9 8.4 7.3 7.5 8.0 7.6 7.9 9.5 NA NA NA Final HbA1c (%)
standard group
0.8* 0.2 1.5 0.5 1.1 0.7 0.6 0.9 2.5 NA NA NA HbA1c
final−initial
Protocol
treatment:
— Insulin
and
metformin
HbA1c
<6%
HbA1c <6.5%
glicazide
alone or in
association
HbA1c<6%
and
available
treatments
Rosiglitazone
and current
therapy
Pioglitazone
and current
therapy
FPG <6
mmol/L and
metformin,
sulfonylureas,
or insulin
HbA1c
<7%
Insulin FPG
<1.4 g/L
and HbA1c
<7%
Intensive
insulin
Tolbutamide
or
Phenformin
Intensive
— Insulin
and
placebo
HbA1c
<9%
Standard
glucose
control (with
target
glycated
haemoglobin
levels)
HbA1c
7-7.9%
and
available
treatments
Placebo and
current
therapy
Placebo and
current
therapy
FPG <15
mmol/L and
diet
1 insulin
injection
every
morning
Insulin Insulin Placebo Standard
FPG=fasting plasma glucose; NA=not available.
*Mean values.
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RESEARCHFigures
Fig 1 Flow of studies through review
Fig 2 Forest plot for all cause mortality and death from cardiovascular causes
Reprints: http://journals.bmj.com/cgi/reprintform Subscribe: http://resources.bmj.com/bmj/subscribers/how-to-subscribe
BMJ 2011;343:d4169 doi: 10.1136/bmj.d4169 Page 8 of 12
RESEARCHFig 3 Forest plot for macrovascular events: myocardial infarction (fatal and non-fatal) and stroke (fatal and non-fatal). Data
on myocardial infarctions not available for PROactive
28
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RESEARCHFig 4 Forest plot for macrovascular event of congestive heart failure
Fig 5 Forest plot for microvascular events: retinopathy and photocoagulation
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RESEARCHFig 6 Forest plot for microvascular events: visual deterioration or blindness, neuropathy, microalbuminuria, renal failure or
doubling of serum creatinine level, and peripheral vascular events (leg revascularisation, peripheral arterial disease, or
intermittent claudication)
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RESEARCHFig 7 Forest plot for microvascular event of amputation (fatal and non-fatal)
Fig 8 Forest plot for severe hypoglycaemia
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